-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $32

Benzinga·09/04/2026 12:45:16
语音播报
Barclays analyst Eliana Merle maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the price target from $43 to $32.